In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Members will acquire treatment right up until illness progression or maybe the participants are not able to tolerate the study drugs. There may be higher treatment lo